<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21050" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Empyema(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garvia</surname>
            <given-names>Veronica</given-names>
          </name>
          <aff>Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Paul</surname>
            <given-names>Manju</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Veronica Garvia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manju Paul declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21050.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Empyema is defined as a collection of pus in the pleural cavity, gram-positive, or culture from the pleural fluid. Empyema is usually associated with pneumonia but may also develop after thoracic surgery or thoracic trauma. In the United States, there are approximately 32,000 cases per year. Empyema is associated with elevated morbidity and mortality, around 20% to 30% of patients affected will either die or required further surgery in the first year after developing empyema. Early intervention is crucial in the management of empyema.<xref ref-type="bibr" rid="article-21050.r1">[1]</xref><xref ref-type="bibr" rid="article-21050.r2">[2]</xref></p>
      </sec>
      <sec id="article-21050.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Around 20% of patients with pneumonia will develop a parapneumonic effusion that may lead to empyema. Seventy percent of patients with empyema have parapneumonic effusion, the other 30% of cases are related to trauma, post-thoracic surgery, esophageal ruptures, or cervical infections, and a small number are not related to previous pneumonia or intervention, this is known as primary empyema.<xref ref-type="bibr" rid="article-21050.r3">[3]</xref><xref ref-type="bibr" rid="article-21050.r4">[4]</xref></p>
        <p>Depending on if the infection is community-acquired or hospital-acquired, the bacteriology of empyema may change. Also, comorbidities of the patients need to be taken into consideration. For community-acquired empyema, gram-positive bacteria are more common, especially S<italic toggle="yes">treptococcus</italic> species. In this setting, the presence of&#x000a0;gram-negative bacteria has been associated with increased comorbidities of patients with alcohol abuse, gastroesophageal reflux disease (GERD), and diabetes. In hospital-acquired empyema,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>, (methicillin-resistant&#x000a0;<italic toggle="yes">S. aureus&#x000a0;</italic>(MRSA)) and&#x000a0;<italic toggle="yes">Pseudomonas</italic> are more common. When related to trauma and surgery <italic toggle="yes">S. aureus</italic> is also the most common agent.</p>
        <p>The incidence of anaerobes when DNA amplification is implemented can be as high as 70%, when regular technics are used, the incidence can drop to 20%. Due to this discrepancy, it is always important to cover for anaerobe organisms despite negative cultures.</p>
        <p>Fungal empyema is rare and is associated with high mortality, the most common fungus associated with it is <italic toggle="yes">Candida</italic> species.<xref ref-type="bibr" rid="article-21050.r5">[5]</xref></p>
      </sec>
      <sec id="article-21050.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Due to the association between pneumonia and empyema, patients at increased risk for pneumonia will also be at higher risk for empyema. Some risk factors have been identified as unique for developing empyema. Among these factors are diabetes mellitus, intravenous drug abuse, immunosuppression, gastric acid reflux, and alcohol abuse.</p>
      </sec>
      <sec id="article-21050.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The development of empyema can be described in a sequence of events. During an inflammatory process such as pneumonia, there is an increase in fluid production in the pleural cavity known as the exudate stage. As the disease progresses microorganisms, usually bacteria, can colonize the fluid and generated an empyema. This fluid is characterized by elevated lactate dehydrogenase, proteins, neutrophils, and dead cells. Macroscopically is a thick opaque fluid&#x000a0;found in the&#x000a0;fibrinopurulent&#x000a0;stage. After the resolution of the infection and as a consequence of the inflammation, there is a process of fibrosis that can lead to restriction of the lung parenchyma. Appropriate and early intervention is vital to decrease complications and mortality.<xref ref-type="bibr" rid="article-21050.r6">[6]</xref><xref ref-type="bibr" rid="article-21050.r7">[7]</xref></p>
      </sec>
      <sec id="article-21050.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation may be similar to pneumonia, and cough, sputum production, fever, and pleuritic-type chest pain may be present. Patients with empyema may have symptoms for a more extended period. Research has shown that patients presented after a median of 15 days after the onset of symptoms. On physical exam there may be a dullness to percussion on the affected area, egophonia, increase palpable fremitus, and fine crackles. However, symptoms and physical exam findings are unspecific. Patients not improving with appropriate&#x000a0;antibiotic therapy should be checked for the possibility of empyema.</p>
        <p>A scoring system has been developed to assess mortality in 3 months upon presentation of patients with empyema. This&#x000a0;system is called the RAPID score. The parameters included in the system are kidney function (<bold>R</bold>enal), <bold>a</bold>ge, presence or albescence of <bold>p</bold>us, hospital-acquired versus community-acquired <bold>i</bold>nfection, and albumin levels (<bold>d</bold>iet). Patients with a score&#x000a0;of&#x000a0;more than 5 had poor outcomes.</p>
      </sec>
      <sec id="article-21050.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Due to the lack of specificity in a clinical presentation, more tests&#x000a0;are needed to establish a diagnosis.<xref ref-type="bibr" rid="article-21050.r8">[8]</xref></p>
        <p>To evaluate for the presence of&#x000a0;any pleural effusion, the first test that should be ordered is a chest x-ray. It is a widely available and simple test, but it is not 100% sensitive. A certain amount of fluid needs to be present to be detected, usually 75 ml in a lateral view, and approximately 175 ml in an anterior view. On an&#x000a0;x-ray, some of the characteristics of a pleural effusion are blunted&#x000a0;due to costodiaphragmatic angles and lungs filled with radiolucent fluid (depending on the size of the effusion).</p>
        <p>If an&#x000a0;effusion is suspected with the chest x-ray, the next step is an ultrasound. Ultrasound is increasingly common because of its benefits, namely because it is widely available, it can be done at a patient's bedside, it is more sensitive at identifying pleural effusions than an x-ray, it allows differentiation between parenchyma and pleural fluid, and it also has a therapeutic use. Ultrasound can be useful in guiding a chest tube placement during thoracentesis. Some empyema characteristics found with ultrasound are homogenous echogenicity, anechoic effusion with hyperechoic septation, pleural thickening and split pleural, separation of the parietal, and visceral pleural by the fluid.</p>
        <p>CT scan of the chest must be done in patients with empyema. It may be an alternative option after a chest&#x000a0;-ray or ultrasound. CT scan ideally&#x000a0;is done with intravenous (IV) contrast to enhance the pleura. CT scan can also be diagnostic and therapeutic, thoracentesis and tube thoracotomy can be performed under this modality. Some of the characteristics on CT scan are thickening of the pleura (present in approximately 80% to 100% patients), pleural enhancement, split pleural sign, bubbles in the absence of tube drainage, and septations. With a CT scan practitioners can better assess the lung parenchyma and the position of a chest tube.</p>
        <p>After thoracentesis, the&#x000a0;obtained&#x000a0;fluid should be sent for analysis and culture.</p>
        <p>Pleural fluid cultures&#x000a0;have poor sensitivity; this can improve if the fluid is not the only stored in sterile containers but also in blood culture bottles. Ideally, the culture fluids should be obtained from&#x000a0;the thoracentesis, chest tube placements, or surgical intervention, but never from pre-existing drainages.</p>
        <p>Pleural fluid analysis is not necessary for the diagnosis of empyema, as mentioned before the presence of pus, gram-positive bacteria, or cultures will yield the diagnosis; nevertheless,&#x000a0;all pleural fluids should be sent for analysis.</p>
      </sec>
      <sec id="article-21050.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Like&#x000a0;with all infections, prompt initiation of antibiotics and source control is fundamental. Treatment of empyema usually involves medical and surgical treatment. In community-acquired empyema, the use of a third or fourth-generation cephalosporin plus metronidazole or ampicillin with a beta-lactamase inhibitor will provided good coverage. In hospital-acquired or trauma-related, and surgery-related empyema, coverage of <italic toggle="yes">Pseudomonas</italic> and MRSA by adding vancomycin, cefepime, and metronidazole or piperacillin-tazobactam&#x000a0;is essential&#x000a0;. Due to the difficulty isolating anaerobes, the coverage for this organism should continue regardless of negative cultures. There is not a proven benefit of intrapleural antibiotics. Antibiotic should be given for 2 to 6 weeks, depending on patient response, source control, and organism.&#x000a0;&#x000a0;<xref ref-type="bibr" rid="article-21050.r9">[9]</xref><xref ref-type="bibr" rid="article-21050.r10">[10]</xref></p>
        <p>Tube thoracostomy is the most common type of drainage, bore tube versus smaller tubes have not shown any difference regarding mortality and prognosis, but bigger tubes are associated with more pain. For this reason, small tubes are frequently placed, generally smaller than 14F. The position of the tube should be&#x000a0;confirming with an x-ray or CT scan. Lack of clinical improvement in the first 24 hours is usually related to tube malposition or blockage. Blockage of the chest tube can be prevented with frequent flushing, but the necessary&#x000a0;amount and frequency of this process is unclear. Any indication of&#x000a0;a persistent fluid or other locations should be addressed with more aggressive therapy including a larger tube, more tubes, or surgery. The chest tube can usually be removed when the daily production of pleural fluid is proximal 350 ml/day or less.</p>
        <p>The use of intrapleural medication has been around for at least 60 years. Fibrinolytics such as urokinase, streptokinase, and tissue plasminogen activator have been tried, as well as, mucolytics such as DNase. The isolated use of fibrinolytics, so far, has not shown differences in mortality or surgical intervention. On the other hand, some studies have shown that the combination of fibrinolytic and mucolytic, specifically TPA and DNase increases the amount of fluid drainage and the need for surgery, unfortunately, no changes in mortality have been shown. Currently, the use of&#x000a0; intrapleural agents is not a standard of care.</p>
        <p>Usually, surgical intervention is the last resource. The main goal of surgical therapy in empyema is the evacuation of the pus from the pleural cavity and lung expansion. In patients requiring surgical intervention in acute empyema, video-assisted thoracotomy (VATS) is the first step. It is a less invasive procedure, there is less blood loss, less pain for the patient, better respiratory outcome, decrease length of stay, and a decreased 30 days mortality.</p>
        <p>There is always a dilemma of when to convert to open-thoracotomy, and some of the clear indications for this are uncontrolled bleeding, damage to a structure that cannot be repaired with laparoscopy, and a patient who is not able to tolerate one-lung ventilation. Also, when the evacuation of the cavity or lung expansion are not achieved with VATS, an open-thoracotomy is indicated.</p>
        <p>After the acute phase, some patients develop fibrosis and lung restriction that can cause dyspnea and exercise-intolerance as symptoms. Decortication may help to alleviate these symptoms and is considered when pulmonary restriction is present 6 months after the resolution of the infection but there are still issues in a patient's quality of life.</p>
      </sec>
      <sec id="article-21050.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Heart failure</p>
          </list-item>
          <list-item>
            <p>Pulmonary infarction</p>
          </list-item>
          <list-item>
            <p>Sequestration</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21050.s9" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Fibrothorax</p>
          </list-item>
          <list-item>
            <p>Respiratory distress</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21050.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Empyema is a common diagnosis in hospitals. Most empyemas follow bacterial pneumonia or unevacuated hemothorax following trauma. Because the condition can be debilitating, it is best managed by an interprofessional team. The key is early treatment before the onset of trapped lung. Thrombolytic therapy only works for early empyema but even when it works, a complete resolution is not always possible.&#x000a0;A&#x000a0;thoracic surgery consult should be made early; if the pleural cavity is emptied of all the fluid/blood, the risk of an empyema are low. However, if there is a delay in treatment, the patient may end up needing VATs or a thoracotomy. Patients with empyema usually have a chest tube and are monitored by nurses on the surgical floor. The prognosis for most patients with early empyema is excellent. However, complete resolution of the X-ray findings may take months. The pulmonary function usually improves rapidly once empyema is surgically managed.<xref ref-type="bibr" rid="article-21050.r1">[1]</xref><xref ref-type="bibr" rid="article-21050.r11">[11]</xref><xref ref-type="bibr" rid="article-21050.r12">[12]</xref> (Level V)</p>
      </sec>
      <sec id="article-21050.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21050&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21050">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/empyema/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21050">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21050/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21050">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21050.s12">
        <fig id="article-21050.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Empyema chronic Image courtesy Dr Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="empyema1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-21050.s13">
        <fig id="article-21050.image.f2" position="float" orientation="portrait">
          <caption>
            <p>GB empyema Image courtesy O Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="empyema__GB" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-21050.s14">
        <fig id="article-21050.image.f3" position="float" orientation="portrait">
          <caption>
            <p>US empyema GB Image courtesy O Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="empyema__GBa" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21050.s15">
        <title>References</title>
        <ref id="article-21050.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bostock</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Millington</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Finley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Contemporary outcomes of surgical management of complex thoracic infections.</article-title>
            <source>J Thorac Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>5421</fpage>
            <page-range>5421-5427</page-range>
            <pub-id pub-id-type="pmid">30416790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Roozendaal</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>van Gool</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sprooten</surname>
                <given-names>RTM</given-names>
              </name>
              <name>
                <surname>Maesen</surname>
                <given-names>BAE</given-names>
              </name>
              <name>
                <surname>Poeze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hulsew&#x000e9;</surname>
                <given-names>KWE</given-names>
              </name>
              <name>
                <surname>Vissers</surname>
                <given-names>YLJ</given-names>
              </name>
              <name>
                <surname>de Loos</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of bronchial rupture in blunt chest trauma: a review of literature.</article-title>
            <source>J Thorac Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>5576</fpage>
            <page-range>5576-5583</page-range>
            <pub-id pub-id-type="pmid">30416808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madhi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Minodier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dubos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zenkhri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dommergues</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mezgueldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levieux</surname>
                <given-names>K</given-names>
              </name>
              <collab>Pneumonia Study Group</collab>
              <name>
                <surname>B&#x000e9;chet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
              <collab>GPIP (Pediatric Infectious Disease Group)</collab>
            </person-group>
            <article-title>Change in Bacterial Causes of Community-Acquired Parapneumonic Effusion and Pleural Empyema in Children 6 Years After 13-Valent Pneumococcal Conjugate Vaccine Implementation.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2019</year>
            <month>Nov</month>
            <day>06</day>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>474</fpage>
            <page-range>474-477</page-range>
            <pub-id pub-id-type="pmid">30407519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liese</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Schoen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van der Linden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goettler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Segerer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Streng</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010-2017: a nationwide surveillance study.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>857</fpage>
            <page-range>857-864</page-range>
            <pub-id pub-id-type="pmid">30395932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makdisi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Makdisi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Contemporary surgical management of thoracic empyema.</article-title>
            <source>J Thorac Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>Suppl 26</issue>
            <fpage>S3069</fpage>
            <page-range>S3069-S3070</page-range>
            <pub-id pub-id-type="pmid">30370082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feller-Kopman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Light</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pleural Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>22</day>
            <volume>378</volume>
            <issue>8</issue>
            <fpage>740</fpage>
            <page-range>740-751</page-range>
            <pub-id pub-id-type="pmid">29466146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Infectious pleural effusion status and treatment progress.</article-title>
            <source>J Thorac Dis</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>4690</fpage>
            <page-range>4690-4699</page-range>
            <pub-id pub-id-type="pmid">29268539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>VATS and Intrapleural Fibrinolytic Therapy for Parapneumonic Empyema.</article-title>
            <source>Ann Thorac Cardiovasc Surg</source>
            <year>2018</year>
            <month>Oct</month>
            <day>19</day>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>263</fpage>
            <page-range>263-264</page-range>
            <pub-id pub-id-type="pmid">29962389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Coller</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Sklansky</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shadman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Thurber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barreda</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Edmonson</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Trends in Hospital Treatment of Empyema in Children in the United States.</article-title>
            <source>J Pediatr</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>202</volume>
            <fpage>245</fpage>
            <page-range>245-251.e1</page-range>
            <pub-id pub-id-type="pmid">30170858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Semenkovich</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Kozower</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Current State of Empyema Management.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>1589</fpage>
            <page-range>1589-1596</page-range>
            <pub-id pub-id-type="pmid">29550205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Touray</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Lindstrom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holdorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Risk Stratification in Patients with Complicated Parapneumonic Effusions and Empyema Using the RAPID Score.</article-title>
            <source>Lung</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>196</volume>
            <issue>5</issue>
            <fpage>623</fpage>
            <page-range>623-629</page-range>
            <pub-id pub-id-type="pmid">30099584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21050.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;fken</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ewig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Volmerig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hecker</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Video-Assisted Thoracoscopic Surgery of Parapneumonic Empyema - a 10-year Single-Centre Experience.</article-title>
            <source>Pneumologie</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>843</fpage>
            <page-range>843-850</page-range>
            <pub-id pub-id-type="pmid">30071540</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
